Thank you for joining us for the First Quarter 2020 Ocular Therapeutix Earnings Conference Call. Currently, all participant lines are in listen-only mode. After the presentation, we will have a question-and-answer session. I will now pass the call to Mr. Donald Notman, Chief Financial Officer. Please proceed.

Thank you, operator. Good morning, everyone, and thank you for joining us on our first quarter 2020 financial results and business update conference call. This morning, before the opening, we issued a press release providing an update on the Company’s product development programs and details of the Company’s financial results for the quarter ended March 31, 2020. The press release can be accessed on the Investors portion of our website at investors.ocutx.com. Leading the call today will be Antony Mattessich, our President and Chief Executive Officer, who will provide a summary of our corporate development and an update on the DEXTENZA commercial launch. Also speaking on the call today will be Dr. Michael Goldstein, our Chief Medical Officer, who will give an update on our clinical developments and pipeline. Following Michael’s remarks, I will provide an overview of the financial highlights for the quarter, before turning the call back over to Antony for a summary and questions. As a reminder, on today’s call, we will be making forward-looking statements regarding our regulatory and product development plans as well as our research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 10-K on file with the SEC. I will now turn the call over to Antony.

Thank you, Donald. And welcome to Ocular Therapeutix's first socially distanced quarterly earnings report. Before I get started, I wanted to note how proud I am of our organizational response to the COVID-19 pandemic. The Company has contributed to the fight against COVID-19 through donations of PPE to local health care providers, and many of our employees have given time to supply food to those most in need in the Bedford, Massachusetts area. Thank you for all of your efforts. Despite the upheaval caused by the coronavirus, the outlook for Ocular continues to brighten. It is good to take stock of the major value drivers and how their prospects have improved in the recent past, due to favorable changes in external business and regulatory environments as well as important developments in the portfolio. One of the great benefits of Ocular Therapeutix is that being a small company with a limited spend, our technology allows us to advance many programs across several of the most valuable segments in ophthalmology. These segments are wet age-related macular degeneration or wet AMD, glaucoma, dry eye disease or DED, and post-surgical inflammation and pain. Let's start with the largest of these value drivers, wet AMD. The global market for wet AMD is nearing $11 billion and growing annually at approximately 8%. A key driver in the treatment selection for wet AMD is durability. The longer treatment works to keep a patient without fluid on a single injection, the greater the attractiveness of the treatment. Current standard of care typically has patients needing reinjection every 4 to 8 weeks. In the space of the last few quarters, OTX-TKI, our intravitreal tyrosine kinase eluting implant designed to deliver up to 6 months of therapy with a single injection has received favorable results in the clinic and benefited from changes in the commercial landscape. In the clinic, our second higher dose cohort has demonstrated for the first time that delivering a tyrosine kinase inhibitor into the eye using our delivery technology has led to a strong clinical signal toward clinically meaningful reductions in retinal thickness in some patients. Michael will soon share with you the latest data. Given the performance in the clinic, we believe that OTX-TKI has the potential to extend the durability of treatment for wet AMD. On the competitive landscape, as many of you are aware, the emergence of retinal vasculitis with brolucizumab leads the market for more durable treatments of wet AMD open for a product that can demonstrate superiority on this parameter. Moving on to glaucoma, another large potential market for possibly the greatest unmet medical need. It's a product that ensures patient compliance. Recent FDA approval of intracameral deliveries of prostaglandin, most notably with the approval of DURYSTA, Allergan’s bimatoprost containing intercameral injection has paved the way for OTX-TIC, our travoprost eluting intracameral implant. We believe we can be a fast follower to Allergan’s DURYSTA and can potentially offer some interesting safety and durability benefits. With the targeted product profile of six months of IOP lowering with the single insert that bioerodes on its own and current data showing an efficacy signal beyond this time point in some subjects and observed to have a favorable safety profile, we are very excited by what we have seen in the early results from this trial and believe OTX-TIC has the potential to become the standard of care for the treatment of elevated IOP. For the treatment of ocular surface diseases such as allergic conjunctivitis and dry eye disease, we have seen positive developments in both our internal programs and in the regulatory environment. On the product side, we are excited by the results of our Phase 3C trial for DEXTENZA in allergic conjunctivitis. Michael will go into the details of that trial, but the big picture is that we believe it will enable us to file an sNDA application for DEXTENZA’s first ocular surface disease indication, ocular itching associated with allergic conjunctivitis and be the first indication in the ophthalmology office environment. Similarly, the environment looks positively changed in our efforts to leverage DEXTENZA that in the largest segment of ocular surface disease, the treatment of dry eye disease. We were very pleased to see that the results of the STRIDE 3 trial for Kala Therapeutics met its primary endpoint, resulting in a high probability of a steroid being approved in a dry eye condition. Clearly, for Ocular and DEXTENZA this is good news that a steroid treatment will likely be indicated in DED, giving us greater confidence and clarity in our development pathway in DED. In the treatment of dry eye disease, we are excited by the potential of both DEXTENZA and our new product OTX-CSI for these ocular surface indications. We believe the market will become a non-abusable, preservative-free steroid-free option that includes the canaliculus and provides a hands-free alternative to the patient. Finally, in the treatment of post-surgical inflammation and pain with DEXTENZA, we're making strides internally and paradoxically, we believe the external post-COVID environment could be even more conducive to a product like DEXTENZA. On the sales side, we recorded $2.1 million in DEXTENZA net revenue for the first quarter. This sales performance represents an increase of 31% over the prior quarter, and is even more notable because of the near-total shutdown in cataract surgeries to begin in the second half of March. To give you a sense of the volume change. We sold nearly 1,000 billable units to ASCs and hospitals in the first two weeks of March, reaching a run rate of nearly $15 million annual sales. We sold only around 300 inserts in the following two weeks as ASCs and hospitals cancelled cataract surgeries due to the coronavirus pandemic. The near total shutdown in cataract surgeries continued through April. We're beginning to see ASCs schedule reopen. While the temporary shutdown is frustrating, particularly because of the momentum we were seeing, we expect to come out of the shutdown better positioned than before. We've had many conversations with anterior segment surgeons as they restart their surgeries in the post-COVID era and have been pleased to hear that their appreciation for the benefits of DEXTENZA has only grown. Clearly, in an environment where infection risk must be minimized, the hands-free option of replacing 70 steroid drops with a single physician administered bioresorbable intracanalicular insert is even more compelling. In summary, Ocular Therapeutix is making tremendous strides in the development of its portfolio, but it is also being helped by changes in the competitive and regulatory environment. As we look at Ocular’s prospects, even a few quarters prior, we see a very different outlook today. Across the spectrum of wet AMD, glaucoma, DED, and prevention of post-surgical pain and inflammation, our products have progressed substantially in the market and are even more attractive than before. With that I will now turn the call over to Mike Goldstein.

Thanks, Antony. Let me begin with an update on our back-of-the-eye program, OTX-TKI. OTX-TKI is a bioresorbable, hydrogel implant containing axitinib, which has anti-angiogenic properties and is delivered by intravitreal injection. It is being developed to treat patients with wet age-related macular degeneration and other retinal diseases, such as diabetic macular edema and retinal vein occlusion. We continue to dose subjects in a multicenter open label Phase 1 clinical trial in Australia that is designed to assess the safety and tolerability of OTX-TKI, as well as to assess preliminary biological activities by measuring anatomical and functional changes. As Antony mentioned, we recently reported encouraging interim data from the ongoing Phase 1 trial in March. In April, Robert Avery, a member of the Data Safety Monitoring Committee overseeing the Phase 1 trial presented interim data on OTX-TKI at the Annual Vit Buckle Society Meeting. These data included an update on the first two fully enrolled cohorts and demonstrated that OTX-TKI in both cohorts was generally observed to be well-tolerated with a favorable safety profile with no ocular serious adverse events. Regarding biological activity, in the interim look in this small data set, there seems to be a dose response with greater clinical response in the higher dose cohort compared to the lower dose cohort. In the higher dose cohort two, OTX-TKI treated subjects showed a decrease in retinal fluid as measured by decreases in intraretinal and/or subretinal fluid with the longest treated subjects with age-related wet macular degeneration now out to be on 4.5 months. Additionally, some patients in cohort 1 who had required frequent anti-VEGF dosing prior to enrollment in the study were shown to potentially not need rescue therapy for as long as 10 months after being treated with OTX-TKI. While the drug product profile is still emerging, we are pleased with the interim data that shows intravitreal injection of a TKI can reduce intraretinal and/or subretinal fluid. There are a number of questions that still need to be addressed as we continue to study the durability of the response, and we have recently amended the current protocol to allow for an even higher dose for the next cohort to be enrolled. Moving to our glaucoma program, OTX-TIC is a bioresorbable travoprost containing hydrogel implant delivered via intracameral injection designed to deliver extended duration of IOP reduction. We continue to enroll subjects with primary open-angle glaucoma or ocular hypertension in a Phase 1 prospective, multicenter open-label dose escalation clinical trial in the United States to evaluate the safety, biological activity, durability, and tolerability of OTX-TIC. In February, we presented interim data at the Glaucoma 360 Conference that took place in San Francisco. Data from the first two fully enrolled cohorts, five subjects in cohort 1 and four subjects in cohort 2, showed decreased IOP in patients receiving the OTX-TIC that was comparable to current standard of care. Topical travoprost placed in the non-study eye throughout the six-month period. The data also showed that the IOP remained consistently decreased for an extended duration of 6 to 9 months in many subjects with a single implant. We also have seen one subject with well-controlled IOP for over 20 months for the single implant. The hydrogel biodegraded in approximately 5 to 7 months in most subjects and we continue to observe that the product is well-tolerated and has a favorable safety profile. From a safety perspective, we have seen no clinically meaningful changes in corneal endothelial cells as measured by slit lamp pachymetry and direct imaging of the endothelial cells. We have now completed enrollment in cohort 2 and cohort 3, with the same dose of travoprost as cohort 1 and a more rapidly degrading hydrogel implant, and are currently enrolling cohort 4, a smaller implant with a lower dose. Enrollment has recently been slowed slightly by COVID-19, but we believe this will pick up as ophthalmic offices open back up for non-emergent patients. Once this trial is complete, we intend to advance the most promising formulations into Phase 2 clinical trials. In the area of ocular surface diseases, which include our work in allergic conjunctivitis and dry eye, we've recently announced positive top-line results for our Phase 3 clinical trial for DEXTENZA in the treatment of ocular itching associated with allergic conjunctivitis. The Phase 3 randomized double-masked parallel arm, placebo-controlled clinical trial enrolled 96 subjects and was conducted across 6 sites in the United States, using Ora’s modified Conjunctival Allergen Challenge models. The primary efficacy measure for this trial was ocular itching on day 8 at 3 minutes, 5 minutes, and 7 minutes post-challenge and included subjects with seasonal and perennial allergens. DEXTENZA-treated subjects demonstrated a statistically significant difference in ocular itching scores, p-value less than 0.0001, compared to vehicle-treated subjects at all three pre-specified time points. An assessment of the secondary endpoint of ocular itching at all other visits, day seven, day eight in the morning, day eight in the afternoon, and 10 minutes following exposure, day 14 and day 15 in the morning and afternoon also showed that DEXTENZA-treated subjects had lower itching scores than vehicle-treated subjects at 3 minutes, 5 minutes, 7 minutes, and 10 minutes, post-CAC, p-value less than 0.05 for all 21 time points, except day 7 at 3 minutes. DEXTENZA was observed to have a favorable safety profile and be well-tolerated with no serious adverse events observed, ocular or non-ocular. No subjects required rescue medication and no subjects experienced elevated intraocular pressure. Overall, the data highlights the compelling product profile targeting a large market that could potentially change the current standard of care for the one-time, long-acting hands-free therapy for the treatment of allergic conjunctivitis. Importantly, as Anthony stated in his comments, this sNDA, if approved, would represent our first in-office indication and expands significantly the versatility and potential for DEXTENZA. In terms of next steps, we plan to complete our review of the full data set in this Phase 3 study, discuss our findings and regulatory pathway with the FDA, and target submission of an sNDA by the end of this year. The largest potential opportunity in the treatment of ocular surface diseases is dry eye disease. We have two programs in dry eye disease, OTX-CSI with an intracanalicular insert which includes the punctum and releases cyclosporine for approximately three months for patients with dry eye disease, and DEXTENZA has potential benefit for patients with episodic dry eye disease. For OTX-CSI, we’ve recently initiated a Phase 1 open-label, single-center clinical trial in the United States to evaluate the safety, efficacy, durability and tolerability of OTX-CSI. We expect to dose the first subjects in the near future. We're very excited about the potential for this hands-free option in helping dry eye disease patients receive the benefits of cyclosporine with potentially greater tolerability and more rapid clinical benefits compared to therapies currently on the market. There continues to be significant interest in studying DEXTENZA in many areas of unmet need with over 70 investigator-initiated trial requests submitted, including many seeking to evaluate DEXTENZA in the treatment of dry eye disease patients. We currently have 9 IIT studies that are active, including one that has completed enrollment. I would now like to turn the call back over to Donald, who will review our first quarter and year-end financial results.

Thanks, Michael. Gross product revenue net of discounts, rebates and returns, which the Company refers to as total net product revenue was $2.6 million for the three months ended March 31, 2020. Net product revenue of DEXTENZA and ReSure Sealant in the first quarter were $2.1 million and $0.5 million, respectively. Research and development expenses for the first quarter were $6.1 million versus $11.3 million for the comparable period in 2019, and primarily reflect a decrease in personnel and unallocated costs due to organizational restructuring announced in November 2019. Selling and marketing expenses for the first quarter were $7.1 million as compared to $3.3 million for the same quarter in 2019. This increase relates almost entirely to support of the commercial launch of DEXTENZA driven primarily by the addition of the field force including key account managers, field reimbursed managers, and medical sales liaisons. Finally, general and administrative expenses were $5.2 million for the first quarter of 2020 versus $5.4 million in the comparable quarter of 2019. The decrease in expenses for the first quarter stemmed primarily from decreased professional costs. With respect to financial results for the first quarter, we reported a net loss of $21.5 million or a loss of $0.41 per share on a basic and diluted basis. This compares to a net loss of $17.1 million or a loss of $0.41 per share on a basic and $0.45 per share on a diluted basis for the same period in 2019. The net loss for the first quarter included $2.4 million in non-cash charges for stock-based compensation and depreciation, compared to $2.5 million for the same quarter in 2019. In addition to the net loss for the quarter, it included a non-cash charge of $3.4 million related to the change in the fair value of the derivative liability associated with our convertible notes. As of May 1, 2020, the Company had approximately 53.4 million shares outstanding. As of March 31, 2020, the Company had $48.2 million in cash and cash equivalents versus $54.4 million at the end of 2019. These cash amounts exclude restricted cash of $1.8 million in both periods. The cash balance benefited during the first quarter from $12.7 million in net proceeds generated from the sale of common stock under the Company's 2019 sales agreement, under which the Company may offer and sell its common stock having aggregate proceeds of up to $50 million from time-to-time. For the period from March 31 to May 6, 2020, the Company has sold additional common stock under the sales agreement, generating net proceeds of $1.7 million. Approximately $1.3 million of common stock remains available to be sold under this facility. Based on the current plans and including related estimates of anticipated cash inflows from DEXTENZA and ReSure Sealant product sales and cash outflows from operating expenses, the Company believes that existing cash and cash equivalents, as of March 31, 2020, together with the second quarter net proceeds through May 6 from sales of common stock pursuant to the sales agreement highlighted previously, will enable the Company to fund planned operating expenses, debt service obligations, and capital expenditure requirements into the first quarter of 2021. This cash guidance is subject to various assumptions including those related to the severity and duration of the COVID-19 pandemic, an expected rebound in cataract surgeries beginning in the third quarter, and other assumptions related to revenues and expenses associated with the commercialization of DEXTENZA, variable expense reductions and the pace of research and clinical development programs, as well as other aspects of the Company’s business. This concludes my comments on the first quarter financial results. And I would like to turn the call back to Antony for some summary thoughts.

Thanks, Donald. So, before opening the call up for questions, let me do a quick summary. The performance of OTX-TKI in the clinic continues to support our product profile that could set a new standard of care for durability, the greatest area of unmet need in treatment of wet AMD. The performance of OTX-TIC in the clinic continues to support a product profile that could set the standard of care for patient compliance, the greatest area of unmet need in the treatment of glaucoma. Our positive Phase 3 trial in allergic conjunctivitis paved the way for Ocular Therapeutix’s first indication in the treatment of an ocular surface disease, where we believe treatment through the intracanalicular route of administration could set a new standard of care. Finally, as cataract surgeries begin to return to normal, we anticipate that DEXTENZA's features and benefits in the prevention of post-surgical inflammation and pain will be enhanced by the fact that DEXTENZA is truly a hands-free alternative that replaces the need for 70 steroid drops and decreases the risk of infection from issues related to patient compliance with this complicated dosing regimen. Due to developments in our pipeline as well as changes in the regulatory, competitive and post-COVID environment, we believe the future has never been brighter for Ocular Therapeutix. With that I'll turn the call over to questions.

Our first question comes from Joe Catanzaro with Piper Sandler. Your line is now open.

Hey, guys. Thanks for taking my questions. Maybe first, two on DEXTENZA. So, we know procedures have been impacted. But just wondering how the process of getting DEXTENZA onto formularies at ASCs has been impacted. Are P&C committee meetings still happening virtually? Is that a process that's still going on? And then, I know it's early, but for ASCs that may have reopened, do you see their initial volumes being higher than their historical volumes to maybe make up for some of the lost procedures they've lost over the last two months or so?

It's really challenging to provide a definitive answer to your questions. The first question is easier to address. The administrative staff is still actively working, which has allowed us to engage in several productive discussions with them. Although many surgeries are currently on hold, we seem to be receiving more attention from them now than when operations were running at full capacity. However, this situation is not uniform; some locations have furloughed staff and are effectively closed. Regarding our market share in the ASCs that have reopened, the current volume is so low that we lack sufficient data to accurately assess our cataract share post-COVID pandemic.

And then, maybe one on OTX-TKI. I guess, how should we think about data flow? We've seen others in the extended bed rest space provide updates every maybe three months, three to six months as they get additional follow-ups. How are you guys thinking about this moving forward? And I guess, could we expect another update this year?

Mike, do you want to have that one?

Sure. So, yes, we will provide an update when we have something meaningful to say. So, we're continuing to follow the patients in the first two cohorts, and we are gearing up to enroll a third higher dose cohort. We currently do plan to provide an update later in the year, probably targeting around the AAO timeframe.

The next question comes from Stacy Ku with Cowen & Company. Your line is now open.

So, a follow-up kind of on your expectations moving forward. Maybe more details or any metrics such as the number of clinics using DEXTENZA and have been closed, or maybe the number of scheduled cataract surgeries that you're aware of potentially using DEXTENZA that's been postponed? And I have a follow-up.

Yes, we're not providing guidance for the future until we observe how the flow progresses in the ASCs. We are seeing a significant reopening of the ASCs with scheduling surgeries. The main question is whether patients will show up to achieve the expected throughput numbers. We notice around 20% to 30% of volume returned in May and anticipate that rising to 50% to 60% in June, aiming for more normalized levels by July. However, this is speculative at this point, as it is early in the process, making it hard to determine exactly how things will unfold. Regarding metrics, we are reporting one key metric that effectively reflects our sales progression, which is the sales of billable units to the ASCs and hospitals. This drug is relatively expensive for those institutions, and they don’t hold inventory. Therefore, when they purchase an insert from the 3PL distributors, it is used quickly. This provides a clear indication of market activity. We averaged about 500 inserts per week in early March before the ASCs began to shut down, impacting that number. We aim to return to 500 per week soon and hopefully increase that significantly as we anticipate gaining a larger share of total cataract volumes due to the advantages our product offers, including the ability to have discussions with ASCs that can integrate us into their protocols and the benefits of a hands-free solution that prevents patients from touching their eyes in numerous instances throughout the month.

Okay. Thank you. And then, just a follow-up question on OTX-TKI. Given what you've observed with the other competitive entrants considering inflammation, maybe you could comment on what you guys are focused on in terms of safety for intravitreal implants?

Hey, Mike. Do you want to handle that?

Sure. I believe we are on track, as many intravitreal injections have experienced inflammation issues with either the vitreous or the retina. This is something we are closely monitoring. So far, none of the patients we've treated have required steroid treatment. From the 12 patients we are tracking, the treatment appears to be very safe and well-tolerated.

Thank you.

Thank you.

Our next question comes from Jonathan Wolleben with JMP Securities. Your line is now open.

Hey, good morning. Congrats on the progress. And thanks for taking the questions.

Good morning.

Just a couple for me. First, for allergic conjunctivitis, can you discuss how you envision DEXTENZA being used in the real world setting? Is this something that you think patients will use proactively, early in an allergy season or something when drops may not be working? And then, any comments on kind of your commercialization strategy?

Yes. With allergic conjunctivitis, given the price differences that we would see in the marketplace between a generic steroid drops and an insert of DEXTENZA for allergic conjunctivitis, you would expect it to be used in a refractory population, and that we would be step-edited by payers. So, what we see the usage of is that this first of all, gets us into the ophthalmologist’s office, which is hugely important to us. And secondly, it's the first ocular surface indication we have where there's a tremendous opportunity in multiple areas within the ocular surface area. But, looking at the type of patient who's likely to get reimbursed, are typically patients who would have failed on drops. And you can fail in drops in a number of ways. You can either fail on drops because they simply don't work from an efficacy standpoint. You can also fail on drops because you're unable to take them or unable to tolerate the preservatives that are in steroid drops or have some issue with dexterity or the ability to adequately dose yourself with an eye drop. That's actually a really significant population. And within ASCs, we certainly would expect to capture that population. But, we would also expect being in the office environment and being in the ocular surface disease area that other ocular surface diseases in this patient type would also be motivating for both the physician and the payer to support a product like DEXTENZA in that environment. So, ASC is a great opportunity in and of itself, but actually, the real opportunity is that it opens the door to much, much wider opportunities in the ocular surface disease space and in the refractory population of people who cannot take drops.

And just one on OTX-CSI, can you discuss beyond safety, what kind of measurements you'd be looking for to determine how this is working and kind of what time points will you be measuring? Thanks.

Sure. Mike, do you want to handle that?

Yes, sure. So, OTX-CSI is a new program. It's a cyclosporine intracanalicular insert that's designed to release cyclosporine for approximately three months. So, you get the advantage of release of the medication, which we know works based on two FDA approvals in the space and you also get the advantage of punctal occlusion, which we also know works as its standard of care in managing dry eye patients. So, super excited about this program. As we mentioned, the study has been initiated. It is a Phase 1 study in patients with dry eye disease. As we mentioned, Phase 1 studies are primarily focused on safety, and we will focus there. We know that cyclosporine works well and we know the hydrogel intracanalicular insert has been well tolerated in many, many patients. So, no concerns there but something we need to follow up. From an efficacy perspective, we will follow signs and symptoms of dry eye disease. So, those would include patient-reported outcomes, using some of the standard metrics, like the OSDI and looking at dry eye symptoms with the visual analog scale. We’ll also look for signs of dry eye as measured by the physicians, which will include things that you'd expect to see in dry eye studies, like corneal fluorescein staining. We're following the patients for four months, and we'll be following both the signs and symptoms over that interval. And then, the plan would then be, once the Phase 1 is completed, to transition to a larger Phase 2 study, later this year.

I think it's important to consider that DEXTENZA in episodic dry eye disease and CSI in chronic disease utilize punctal occlusion, a standard treatment for dry eye. From a marketing perspective, it is much easier to help physicians adopt a practice they are already familiar with, such as including the punctum, while also taking advantage of drug release without preservatives. This presents a significant opportunity for us to align with market practices rather than requiring practitioners to change their established procedures. Additionally, there is a procedure code associated with it that stands alone, which is 356T, applicable to both products. Over time, we anticipate that 356T will be classified as a category one procedure code that operates independently and is not contingent upon other procedures in the ocular surface space or ophthalmic surgery.

That's very helpful. Thanks again for taking the questions.

Thank you.

I'm showing no further questions in queue at this time. Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.